If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMortgage Advice Bureau Regulatory News (MAB1)

Share Price Information for Mortgage Advice Bureau (MAB1)

Share Price is delayed by 15 minutes
Get Live Data
526.00    -4.00 (-0.75%)
Bid:
521.00
Ask:
534.00
Spread: 13.00 (2.495%)
Market Cap: £303.05m
MAB1 Live PriceLast checked at - London Stock Exchange

Intraday Mortgage Advice Bureau Share Chart

Trading Update

23 Jan 2025 07:00

RNS Number : 3653U
Mortgage Advice Bureau (Hldgs) PLC
23 January 2025
Β 

Β This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018. The person responsible for this announcement is Emilie McCarthy, CFO.

Β 

23 January 2025

Β 

Mortgage Advice Bureau (Holdings) plc

("MAB" or the "Group")

Β 

Trading Update

Board Changes

Β 

Mortgage Advice Bureau (Holdings) plc (AIM: MAB1) today issues a trading update for the year ended 31 December 2024, ahead of publishing its final results on Tuesday, 18 March 2025.

Β 

Year ended 31 December 2024

Group revenue for year ended 31 December 2024 increased by 11% to c.Β£266m (2023: Β£239.5m), which is significantly higher than the estimated 4% growth (1) in UK gross lending for the same period. The Board expects to report growth in Adjusted PBT for the year of c. 31% to c. Β£30.5m (2023: Β£23.2m) which is c. 4% ahead of consensus (2), excluding the Β£1.5m positive impact of the capitalisation of Midas platform internal development costs in 2024.

MAB's number of mainstream advisers grew modestly in the second half, increasing to 1,941 at the year-end (2023: 1918). However, lower than expected growth in adviser numbers was more than offset by a significant rise in productivity. The average revenue per mainstream adviser grew c.12% to c. Β£138k (2023: Β£123.5k). Improving operational efficiency is a key area of focus across the Group, supported by technology enhancements and lead-generation initiatives.

Current trading and outlook

Clear signs of pent-up demand were evidenced by the increase in mortgage applications in Q4 2024 (+15% compared to Q4 2023) and we expect this positive momentum to be maintained. UK Finance forecasts (1) gross new lending to rise 11% in 2025 in Β£235bn, which we believe is a realistic estimate.

In addition, the delivery of new technology enhancements and lead generation initiatives are expected to drive further growth this year, with many AR firms expecting to see adviser numbers increase, alongside a continued focus on increasing profitability through rising productivity.

Β 

Β 

Β 

Β 

Β 

Board changes

MAB is pleased to announce that subject to regulatory approval, Paul Gill, Chief Risk Officer, will be joining the Board as an Executive Director.

Β 

David Preece, Non-Executive Director, has decided not to seek re-election at the next AGM. The Board would like to thank David for his enormous contribution to MAB, as an Executive Director from 2004 to 2019, and as a Non-Executive Director since 2019.

Β 

The Board intends to add two additional Independent Non-Executive Directors.

Β 

Capital Markets Day

As previously announced, MAB will host a Capital Markets Day in London from 14:00 to 17:00 on 5 February 2025. The event will be held at the London Stock Exchange and will be webcast live for those who cannot attend in person.

Β 

The event will include updates on strategy, growth plans, technology and lead generation initiatives from our Executive Directors and members of our senior management team. We will also discuss medium-term targets and a proposed new capital allocation policy, further details of which will be pre-released via RNS on 4 February 2025.

Β 

If you would like to register your interest in the event, please contact Camarco: mab@camarco.co.uk.

Β 

Β 

Peter Brodnicki, CEO of MAB, commented:

"Despite two challenging years in terms of UK mortgage volumes, I am very pleased with how MAB has performed. We have increased strategic spend over this period and are starting to see the benefits of this come through in the positive momentum we're building.

Β 

We expect purchase transactions to steadily increase over the next year, whilst several years of strong refinancing transactions will provide additional opportunities for growth.

Β 

We are seeing increased optimism among many of our ARs, and as a result, expect to see organic growth in adviser numbers start to return in a more meaningful way. Following a slower period in terms of new AR recruitment, we plan to onboard more firms this year while continuing to explore value-accretive acquisitions.

Β 

The step up in productivity in 2024 has been very pleasing, so our focus for this year is on maintaining that momentum, supported by development in technology and AI, and our continued focus on lead generation."

Β 

(1) - UK Finance Mortgage Market Forecasts published in December 2024

(2) - Consensus estimate 2024 adjusted PBT - Β£29.2m.Β 

Β 

Β 

Enquiries:

Β 

Mortgage Advice Bureau (Holdings) plc

Via Camarco

Β 

Peter Brodnicki, Chief Executive Officer

Ben Thompson, Deputy Chief Executive Officer

Emilie McCarthy, Chief Financial Officer

Β 

Nominated Adviser and Joint Broker

Keefe, Bruyette & Woods, a Stifel Company

Erik Anderson / Nick Harland / Francis North / Harry Billen

Β 

Β 

+44 (0)20 7710 7600

Joint Broker

Peel Hunt LLP

Andrew Buchanan / Oliver Jackson

Β 

Β 

Β 

+44 (0) 20 7418 8900

Financial PR

Camarco

Tom Huddart / Louise Dolan / Letaba Rimell

Β 

Β 

mab@camarco.co.uk

+44 (0) 203 757 4980

Investor Relations

Investor.relations@mab.org.uk

Β 

About Mortgage Advice Bureau:

Β 

MAB is one of the UK's leading consumer intermediary brands and specialist networks for mortgage advisers.Β 

Β 

Through its partner firms known as Appointed Representatives ("ARs"), MAB has approximately 2,000 advisers providing expert advice to customers on a range of mortgage, specialist lending, protection, and general insurance products. MAB supports its AR firms with proprietary technology and services, including adviser recruitment and lead generation, learning and development, compliance auditing and supervision, and digitalΒ marketing and website solutions.

Β 

For more information, visitΒ www.mortgageadvicebureau.com

Β 

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Β 
END
Β 
Β 
TSTFFFFILDIFFIE
Date   Source Headline
5th Mar 202511:29 amRNSDirector/PDMR Shareholding
26th Feb 20257:00 amRNS-RNotice of Investor Presentation
18th Feb 20253:57 pmRNSDirector/PDMR Shareholding
17th Feb 20253:29 pmRNSHolding(s) in Company
4th Feb 20257:00 amRNSBusiness Update
31st Jan 20253:16 pmRNSDirector/PDMR Shareholding
23rd Jan 20257:00 amRNSTrading Update
15th Jan 202512:06 pmRNSDirector/PDMR Shareholding
14th Jan 20253:09 pmRNSBlock listing Interim Review
13th Jan 20259:19 amRNSHolding(s) in Company
31st Dec 202411:56 amRNSDirector/PDMR Shareholding
17th Dec 202411:40 amRNSDirectors' Shareholdings and PDMR notification
2nd Dec 202411:40 amRNSDirector/PDMR Shareholding
15th Nov 20249:41 amRNSDirector/PDMR Shareholding
14th Nov 202411:09 amRNSDirector/PDMR Shareholding
13th Nov 20241:53 pmRNSHolding(s) in Company
13th Nov 20247:00 amRNSNotice of Capital Markets Day
12th Nov 20249:14 amRNSHolding(s) in Company
12th Nov 20247:00 amRNSAppointment of Nominated Adviser and Joint Broker
4th Nov 20249:09 amRNSDirectors' Shareholdings and PDMR notification
28th Oct 20249:43 amRNSNotification of Major Holdings
15th Oct 20242:47 pmRNSDirectors' Shareholdings and PDMR notification
4th Oct 202412:16 pmRNSDirectors' Shareholdings and PDMR Notification
2nd Oct 20245:15 pmRNSNotification of Major Holdings
30th Sep 20244:19 pmRNSDirectors' Shareholdings and PDMR notification
30th Sep 202411:58 amRNSDirectors' Shareholdings and PDMR notification
30th Sep 20249:42 amRNSDirectors' Shareholdings and PDMR notification
25th Sep 20247:00 amRNSDirectors' Shareholdings and PDMR notification
24th Sep 20247:00 amRNSInterim Results
17th Sep 20241:44 pmRNSDirectors' Shareholdings and PDMR notification
17th Sep 20249:16 amRNSNotification of Major Holdings
30th Aug 20245:17 pmRNSDirectors' Shareholdings and PDMR notification
15th Aug 20243:01 pmRNSDirectors' Shareholdings and PDMR notification
31st Jul 20245:35 pmRNSDirectors' Shareholdings and PDMR notification
25th Jul 20247:00 amRNSTrading Update
22nd Jul 20248:02 amRNSDirectors' Shareholdings and PDMR notification
22nd Jul 20247:00 amRNSDirectors' Shareholdings and PDMR notification
12th Jul 20241:19 pmRNSBlock listing Interim Review
1st Jul 20247:00 amRNSDirector/PDMR Shareholding
25th Jun 20241:57 pmRNSNotification of Major Holdings
25th Jun 20247:00 amRNSNotification of Major Holdings
21st Jun 20243:06 pmRNSNotification of Major Holdings
17th Jun 20245:49 pmRNSDirector/PDMR Shareholding
13th Jun 202412:39 pmRNSDirector/PDMR Shareholding and TVR
12th Jun 20244:46 pmRNSNotification of Major Holdings
4th Jun 20244:18 pmRNSNotification of Major Holdings
31st May 202410:36 amRNSDirectors' Shareholdings and PDMR notification
29th May 20247:00 amRNSRelated Party Transaction
28th May 20243:56 pmRNSNotification of Major Holdings
23rd May 20247:00 amRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.